---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-102917"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2026-08-28T14:31:00+00:00"
generated_at: "2026-08-28T14:32:14.383571+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Quoin reports positive QRX003 interim data, raises up to $50M in private placement

## Summary
- Private placement up to $50M: $30.8M upfront at $4.88/ADS+warrant, 6,305,300 ADSs and warrants for 3,152,650 ADSs.
- Net proceeds ~$29M at Aug 31 close; funds into 2H 2029; proceeds for QRX003 development and general corporate.
- Phase 2/3 CL-QRX003-004: 4/6 (66.7%) met primary endpoint (≥1-grade IGA improvement), p=0.0087 vs α=0.0215.
- Secondary GIC endpoint significant (p=0.007); no treatment-related SAEs; recruitment done by end 2026, topline 2Q 2027.
- Exchange agreements: issued 222,574 ADSs to settle ~$1.146M accrued interest on 2020 notes.

## SEC filing metadata
- accession: 0001104659-26-102917
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2026-08-28T14:31:00+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465926102917/0001104659-26-102917-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465926102917/tm2624258d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-102917
- JSON: https://secwatch.observer/filing/0001104659-26-102917.json
- Plain text: https://secwatch.observer/filing/0001104659-26-102917.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.